The addition of obinutuzumab to standard care increased the complete renal response rate by 13.4 percentage points in patients with active proliferative lupus nephritis. Obinutuzumab, an anti-CD20 ...

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

Her medical history was significant for a diagnosis of SLE 3 years earlier, which was made on the basis of polyarthritis, pleurisy, hemolytic anemia, biopsy-proven WHO Class IV lupus nephritis ...

yahoo.com Objective To compare the efficacy of tacrolimus (TAC) and mycophenolate mofetil (MMF) for the initial therapy of lupus nephritis (LN ... Results 150 patients (92% women; aged 35.5±12.8 years ...

Background Long-term immunosuppressive treatment does not efficiently prevent relapses of lupus nephritis (LN). This investigator-initiated ... biopsy-proven proliferative WHO class III, IV, Vc or Vd ...

5 6 Here, we aim to showcase ... (E) Serum NGAL in patients with SLE with histologically proven class III or IV membranoproliferative lupus nephritis (MPLN+) as opposed to those without (MPLN−). (F) ...

Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, announces the appointment of Dr. Klaus Edvardsen as its new Chief Medical ...

lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis. This effort aligns with Century’s ongoing Phase 1 CALiPSO-1 trial, which similarly evaluates CNTY-101 ...